Sign up USA
Proactive Investors - Run By Investors For Investors

Catabasis surges after successful mid-stage trial of its DMD treatment

Catabasis’ edasalonexent tablet helped to preserve muscle function and sustained “disease-modifying effects” in boys with DMD, while no side effects were observed
boy walking on beach
DMD almost exclusively affects young boys and there is current no known cure

Catabasis Pharmaceuticals Inc (NASDAQ:CATB) surged on Tuesday after the biopharma reported positive results from a mid-stage study of its Duchenne muscular dystrophy treatment.

In the trial, the company’s edasalonexent tablet helped to preserve muscle function and sustained “disease-modifying effects” in boys with DMD, while no side effects were observed.

Consistent improvements in all assessments of muscle function were observed after more than a year of treatment compared to the rate of change in the pre-specified control period.

DMD is a rare muscle-wasting disease that almost exclusively affects only young boys, for which there is currently no known cure.

Importantly, Catabasis is looking to treat all DMD sufferers with edasalonexent rather than just a subset of patients.

A pivotal phase III trial is scheduled to get underway in the first half of this year, with top-line data expected in 2020.

“We are thrilled to see this preservation of muscle function and substantial slowing of disease progression in boys following more than a year of edasalonexent treatment. This effect has the potential to be extremely impactful for boys affected by Duchenne,” said chief executive Jill Milne.

“Building on the results previously reported for edasalonexent treatment in patients up to 36 weeks, these new data at 48 and 60 weeks show that edasalonexent continued to slow progression of the disease.”

Catabasis shares soared by a quarter to US$1.57 on Tuesday.

View full CATB profile View Profile

Catabasis Pharma Timeline

Related Articles

tumour cells
July 25 2018
Sign-off by the US Food & Drug Administration is considered the "global standard for approval", the company said
bacteria
September 20 2018
Following the disappointment of its DMD treatment over summer, Summit is leveraging its Discuva platform to develop new antibiotics, which doctors are in desperate need of
blood samples in test tubes
October 25 2018
The NYSE-listed company has designed a routine blood test to screen for colorectal and prostate cancers that reduces the need for more invasive colonoscopies and biopsies
Copyright © Proactiveinvestors.com, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use